Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$11.78
$0.26(2.21%)
At close: 4:00 PM EDT
$11.78
$0.26(2.21%)
Day’s Range― - ―
52-Week Range$4.65 - $18.89
Previous CloseN/A
Volume3.24M
Average Volume (3M)4.80M
Market Cap
$1.96B
Enterprise Value$1.24K
Total Cash (Recent Filing)$212.66M
Total Debt (Recent Filing)$38.00M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding106,799,870
10 Day Avg. Volume6,824,540
30 Day Avg. Volume4,796,751
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)10.20
P/FCF Ratio-8.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.88Price Target Upside34.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.07
Revenue Forecast (FY)$80.88M
Bulls Say, Bears Say
Bulls Say
Clinical Adoption And Volume GrowthRapid testing growth and very high physician retention indicate increasing clinical adoption and customer stickiness. Sustained utilization can expand recurring service revenue and improve operating leverage as Personalis scales its oncology testing platform.
Reimbursement And Product ExpansionLive Medicare coverage improves the path from test volume to reimbursed revenue, while Variant Tracker broadens clinical utility beyond MRD detection. Together, these developments can support higher-value offerings and more durable adoption.
Liquidity And Strategic ScaleA substantial cash balance and limited debt provide resources to fund commercialization and product development. The proposed Tempus combination could add distribution, data, and AI capabilities, potentially accelerating scale if approvals are obtained.
Bears Say
Persistent Revenue DeclineThe revenue contraction shows that growth in newer clinical and MRD programs has not yet offset declining legacy and Moderna-related activity. This creates execution risk and leaves the business dependent on successful conversion of its strategic pipeline.
Severe Margin DeteriorationGross margin near breakeven indicates that current testing economics are not yet sustainable. Recovery depends on reimbursement and favorable revenue mix, so delays could prolong losses and limit the profitability of volume growth.
Heavy Cash Burn And Reimbursement RiskLarge projected cash consumption increases funding dependence despite current liquidity. Because improved margins require additional coverage decisions and payer adoption, uncertain timing could extend the period of negative cash flow and accelerate capital depletion.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $4.65 and its highest was $18.89 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $1.96B.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.263 by -$0.037.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.26.
How many shares outstanding does Personalis have?
Personalis has 106,799,870 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.263. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.88 (34.76% Upside)
$15.88 (34.76% Upside)
Blogger Sentiment
Neutral
PSNL Sentiment 55%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 449.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.66%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
PSNL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$15.88
▲(34.76% Upside)
Technical Analysis
Ownership Overview
13.00% Insiders
11.36% Mutual Funds
43.27% Other Institutional Investors
17.59% Public Companies and
Individual Investors